{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:42:40Z","timestamp":1788370960304,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,24]],"date-time":"2023-12-24T00:00:00Z","timestamp":1703376000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["CAN 2018\/362"],"award-info":[{"award-number":["CAN 2018\/362"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Computers in Biology and Medicine"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.compbiomed.2023.107889","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T01:38:37Z","timestamp":1703122717000},"page":"107889","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Synergy and antagonism between azacitidine and FLT3 inhibitors"],"prefix":"10.1016","volume":"169","author":[{"given":"Jingmei","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8696-3104","authenticated-orcid":false,"given":"Ran","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.compbiomed.2023.107889_b1","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.compbiomed.2023.107889_b2","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2014-08-551499","article-title":"How I treat the older patient with acute myeloid leukemia","volume":"125","author":"Ossenkoppele","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.compbiomed.2023.107889_b3","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s11899-015-0257-2","article-title":"Elderly acute myeloid leukemia: assessing risk","volume":"10","author":"Klepin","year":"2015","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"21","key":"10.1016\/j.compbiomed.2023.107889_b4","first-page":"2670","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"Clin. Oncol."},{"issue":"4","key":"10.1016\/j.compbiomed.2023.107889_b5","first-page":"562","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","volume":"28","author":"Fenaux","year":"2010","journal-title":"Clin. Oncol."},{"issue":"3","key":"10.1016\/j.compbiomed.2023.107889_b6","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with \u00bf30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.compbiomed.2023.107889_b7","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1182\/blood-2018-10-879866","article-title":"Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients","volume":"133","author":"Huls","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.compbiomed.2023.107889_b8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ijc.23607","article-title":"Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine","volume":"123","author":"Stresemann","year":"2008","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.compbiomed.2023.107889_b9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1182\/hematology.2020000089","article-title":"Management of toxicities associated with targeted therapies for acute myeloid leukemia: when to push through and when to stop","volume":"2020","author":"Wang","year":"2020","journal-title":"Hematology"},{"key":"10.1016\/j.compbiomed.2023.107889_b10","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S2152-2650(20)30441-9","article-title":"FLT3 inhibition in acute myeloid leukemia","volume":"20","author":"Smith","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"8","key":"10.1016\/j.compbiomed.2023.107889_b11","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1021\/acs.jcim.0c00544","article-title":"Pattern and dynamics of FLT3 duplications","volume":"60","author":"Todde","year":"2020","journal-title":"J. Chem. Inf. Model."},{"issue":"1","key":"10.1016\/j.compbiomed.2023.107889_b12","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188666","article-title":"The molecular mechanisms behind activation of FLT3 in acute myeloid leukemia and resistance to therapy by selective inhibitors","volume":"1877","author":"Friedman","year":"2022","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"6","key":"10.1016\/j.compbiomed.2023.107889_b13","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-022-00687-5","article-title":"Resistance to targeted therapies: delving into FLT3 and IDH","volume":"12","author":"Desikan","year":"2022","journal-title":"Blood Cancer J."},{"issue":"2","key":"10.1016\/j.compbiomed.2023.107889_b14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1158\/2643-3230.BCD-20-0210","article-title":"Understanding FLT3 inhibitor resistance to rationalize combinatorial AML therapies","volume":"2","author":"Shastri","year":"2020","journal-title":"Blood Cancer Discov."},{"issue":"1","key":"10.1016\/j.compbiomed.2023.107889_b15","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-5690-5","article-title":"Stochastic modelling of tyrosine kinase inhibitor rotation therapy in chronic myeloid leukaemia","volume":"19","author":"Lindstr\u00f6m","year":"2019","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.compbiomed.2023.107889_b16","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-021-01856-5","article-title":"Combating drug resistance in acute myeloid leukaemia by drug rotations: the effects of quizartinib and pexidartinib","volume":"21","author":"Yang","year":"2021","journal-title":"Cancer Cell Int."},{"issue":"1","key":"10.1016\/j.compbiomed.2023.107889_b17","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-09048-5","article-title":"Rotating between ponatinib and imatinib temporarily increases the efficacy of imatinib as shown in a chronic myeloid leukaemia model","volume":"12","author":"Lindstr\u00f6m","year":"2022","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.compbiomed.2023.107889_b18","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-020-06782-9","article-title":"The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib","volume":"20","author":"Lindstr\u00f6m","year":"2020","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.compbiomed.2023.107889_b19","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-023-03000-x","article-title":"Combination strategies to overcome drug resistance in FLT+ acute myeloid leukaemia","volume":"23","author":"Yang","year":"2023","journal-title":"Cancer Cell Int."},{"issue":"6","key":"10.1016\/j.compbiomed.2023.107889_b20","first-page":"285","article-title":"The problem of synergism and antagonism of combined drugs","volume":"3","author":"Loewe","year":"1953","journal-title":"Arzneimittelforschung"},{"issue":"4","key":"10.1016\/j.compbiomed.2023.107889_b21","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1128\/br.20.4.243-258.1956","article-title":"The calculation of microbial assays","volume":"20","author":"Bliss","year":"1956","journal-title":"Bacteriol. Rev."},{"issue":"11","key":"10.1016\/j.compbiomed.2023.107889_b22","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1177\/1947601912440575","article-title":"Quantitative methods for assessing drug synergism","volume":"2","author":"Tallarida","year":"2011","journal-title":"Genes Cancer"},{"issue":"3","key":"10.1016\/j.compbiomed.2023.107889_b23","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.149","article-title":"Analysis of drug combinations: current methodological landscape","volume":"3","author":"Foucquier","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"issue":"2","key":"10.1016\/j.compbiomed.2023.107889_b24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cels.2019.01.003","article-title":"Quantifying drug combination synergy along potency and efficacy axes","volume":"8","author":"Meyer","year":"2019","journal-title":"Cell Syst."},{"key":"10.1016\/j.compbiomed.2023.107889_b25","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2021.100046","article-title":"Pharmacological interactions: Synergism, or not synergism, that is the question","volume":"2","author":"Calzetta","year":"2021","journal-title":"Curr. Res. Pharmacol. Drug. Discov."},{"key":"10.1016\/j.compbiomed.2023.107889_b26","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2022.100110","article-title":"Evaluation of synergism in drug combinations and reference models for future orientations in oncology","volume":"3","author":"Duarte","year":"2022","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"issue":"1","key":"10.1016\/j.compbiomed.2023.107889_b27","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev-cancerbio-061421-020411","article-title":"Rationales for combining therapies to treat cancer: independent action, response correlation, and collateral sensitivity versus synergy","volume":"7","author":"Schmidt","year":"2023","journal-title":"Ann. Rev. Cancer Biol."},{"issue":"1","key":"10.1016\/j.compbiomed.2023.107889_b28","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-29793-5","article-title":"Bipartite network models to design combination therapies in acute myeloid leukaemia","volume":"13","author":"Jafari","year":"2022","journal-title":"Nature Commun."},{"issue":"4","key":"10.1016\/j.compbiomed.2023.107889_b29","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.slasd.2023.04.004","article-title":"High-throughput approaches to uncover synergistic drug combinations in leukemia","volume":"28","author":"Chory","year":"2023","journal-title":"SLAS Discov."},{"issue":"W1","key":"10.1016\/j.compbiomed.2023.107889_b30","doi-asserted-by":"crossref","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res."},{"issue":"19","key":"10.1016\/j.compbiomed.2023.107889_b31","doi-asserted-by":"crossref","first-page":"14664","DOI":"10.1021\/acs.jmedchem.1c01196","article-title":"Discovery of a potent FLT3 inhibitor (LT-850-166) with the capacity of overcoming a variety of FLT3 mutations","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.compbiomed.2023.107889_b32","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1021\/acs.jmedchem.7b01261","article-title":"Discovery of 4-((7 H-Pyrrolo [2, 3-d] pyrimidin-4-yl) amino)-N-(4-((4-methylpiperazin-1-yl) methyl) phenyl)-1 H-pyrazole-3-carboxamide (FN-1501), an FLT3-and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia","volume":"61","author":"Wang","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.compbiomed.2023.107889_b33","article-title":"A phase I clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of FN-1501 monotherapy in patients with advanced solid tumors","author":"Richardson","year":"2019","journal-title":"Clin. Oncol."},{"issue":"13_Supplement","key":"10.1016\/j.compbiomed.2023.107889_b34","doi-asserted-by":"crossref","first-page":"CT131","DOI":"10.1158\/1538-7445.AM2021-CT131","article-title":"Abstract CT131: A Phase I safety and tolerance study of FN-1501, a novel FLT3 inhibitor, in patients with advanced solid tumors and acute myeloid leukemia","volume":"81","author":"Richardson","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.compbiomed.2023.107889_b35","article-title":"Phase 1 first-in-human study of irreversible FLT3 inhibitor FF-10101-01 in relapsed or refractory acute myeloid leukemia","author":"Levis","year":"2021","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.compbiomed.2023.107889_b36","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102238","article-title":"Allosteric enhancement of the BCR-Abl1 kinase inhibition activity of nilotinib by co-binding of asciminib","volume":"298","author":"Oruganti","year":"2022","journal-title":"J. Biol. Chem."},{"issue":"17","key":"10.1016\/j.compbiomed.2023.107889_b37","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1182\/blood.2021014586","article-title":"Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3 mut+ AML ineligible for intensive chemotherapy","volume":"140","author":"Wang","year":"2022","journal-title":"Blood"},{"issue":"D1","key":"10.1016\/j.compbiomed.2023.107889_b38","doi-asserted-by":"crossref","first-page":"D1045","DOI":"10.1093\/nar\/gkv1072","article-title":"BindingDB in 2015: A public database for medicinal chemistry, computational chemistry and systems pharmacology","volume":"44","author":"Gilson","year":"2015","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"10.1016\/j.compbiomed.2023.107889_b39","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Genom. Proteom. Bioinform."},{"issue":"5","key":"10.1016\/j.compbiomed.2023.107889_b40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1006752","article-title":"Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer","volume":"15","author":"Malyutina","year":"2019","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.compbiomed.2023.107889_b41","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","article-title":"Searching for drug synergy in complex dose\u2013response landscapes using an interaction potency model","volume":"13","author":"Yadav","year":"2015","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.compbiomed.2023.107889_b42","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.2147\/DDDT.S318515","article-title":"The synergistic effect of ginkgo biloba extract 50 and aspirin against platelet aggregation","author":"Ke","year":"2021","journal-title":"Drug Des. Devel. Ther."}],"container-title":["Computers in Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010482523013549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010482523013549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T01:01:16Z","timestamp":1720573276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010482523013549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":42,"alternative-id":["S0010482523013549"],"URL":"https:\/\/doi.org\/10.1016\/j.compbiomed.2023.107889","relation":{},"ISSN":["0010-4825"],"issn-type":[{"value":"0010-4825","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergy and antagonism between azacitidine and FLT3 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Computers in Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.compbiomed.2023.107889","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107889"}}